500 - 3-Year Follow-up Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, …
Transplantation and cellular therapy, Vol.29(2), pp.S374-S374
500 - 3-Year Follow-up Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Creators
Sattva S. Neelapu
Julio C. Chavez
Alison R. Sehgal
Narendranath Epperla
Matthew L. Ulrickson
Emmanuel Bachy
Pashna N. Munshi
Carla Casulo
David G. Maloney
Sven de Vos
Ran Reshef
Lori A. Leslie
Olalekan O. Oluwole
Ibrahim Yakoub-Agha
Rashmi Khanal
Joseph Rosenblatt
Jiali Yan
Qinghua Song
Weixin Peng
Christine Lui
Jacob Wulf
Rhine R. Shen
Soumya Poddar
Harry Miao
Sara Beygi
Caron A. Jacobson
Publication Details
Transplantation and cellular therapy, Vol.29(2), pp.S374-S374
Publisher
Elsevier Inc
Academic Unit
Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology